Top Markets
#1 Islamic Coin Islamic Coin +152.31%
#2 Bitway Bitway +45.45%
#3 Starpower Starpower +38.77%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +32.39%
#5 aelf aelf +25.26%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.23%
#7 SkyAI SkyAI +19.94%
#8 Pons Pons +17.46%
#9 Bedrock Bedrock +15.88%
#10 Decred Decred +14.18%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
GenSight Biologics S.A. GenSight Biologics S.A.

GenSight Biologics S.A.

SIGHT
Rank in Stocks #29770
GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on... GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.
Share Price
$0.12122506
Market Cap
$19.76M
Change (1 day)
-2.29%
Change (1 year)
-39.86%
Country
FR
Trade GenSight Biologics S.A. (SIGHT)

Category

Healthcare
Operating Margin for GenSight Biologics S.A. (SIGHT)
Operating Margin as of 2026 TTM: 0.00%
According to GenSight Biologics S.A. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for GenSight Biologics S.A. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.